chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Client became hypertensive and diaphoretic after vaccine administration.  BP was 69/49, HR 42, Glucose 136.  Client was evaluated by Fire Rescue.  Fire Rescue called and patient declined transport to Medical Center ER at 1:58 pm.
Intermittent fever up to 103 degrees, irritability symptoms began 10 days after immunization with MMR, Varicella, HIB, and Prevnar.  Treatment was supportive with APAP and or/ Ibuprofen.
Has been sick ever since. Tired, no appetite, nauseated, pale. I observed listless, dullness in eyes. Has appt with PCP at 1PM 3/17/05.
Confusion, Headache, Myalgia, Fever, SkinRash, Rash, FATIGUE, INJECTION SITE PAIN Narrative:
put the needled in and he said that the needle was empty and had to do it again/they felt like he push it in,/he came back  with another needle and put another needle in their arm.; This spontaneous case was reported by a consumer and describes the occurrence of WRONG TECHNIQUE IN DEVICE USAGE PROCESS (put the needled in and he said that the needle was empty and had to do it again/they felt like he push it in,/he came back  with another needle and put another needle in their arm.) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Apr-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Apr-2022, the patient experienced WRONG TECHNIQUE IN DEVICE USAGE PROCESS (put the needled in and he said that the needle was empty and had to do it again/they felt like he push it in,/he came back  with another needle and put another needle in their arm.). At the time of the report, WRONG TECHNIQUE IN DEVICE USAGE PROCESS (put the needled in and he said that the needle was empty and had to do it again/they felt like he push it in,/he came back  with another needle and put another needle in their arm.) outcome was unknown.            Concomitant medication was not provided. Patient got their second booster on Friday 01-Apr-2022 Treatment information was not provided.
This case was reported by a consumer and described the occurrence of attention deficit hyperactivity disorder in a 5 yr old female pt who received hep A vaccine inactivated (Havrix). A physician or other health care professional has not verified this report. On an unspecified date in Jul 2001, the pt received a dose of Havrix (a dose number not specified). Approx two months later, on an unspecified date in Sep 2001, the pt experienced attention deficit hyperactivity disorder and was seen at a physician's office. The reporter stated that the pt's sister also has attention deficit hyperactivity disorder, but it is unk if she received hep A vaccine. The event was unresolved.
Right Upper Arm: 10cm x 5cm area of warmth/erythema, no enduration
13 year old female with developing skin rash on face, arms and legs, post vax. Pt was treated with Atarax 25mg and calamine lotion.
30 mins after the injection in left arm, left side of my body became heavy and sluggish. Left ear started popping as if air pressure or elevation changed in a plane. Hearing was affected in left ear and also got a headache.  By the evening lower back, upper back and neck felt like it was recovering from a muscle spasm.   Next day:  Both arms and hands began with tingling and burning sensations  back and neck still tight   Day 3,4 and 5: Arm and hands seem to be better but its still present and the back and neck still feel tight
pt recv vax; screaming, was inconsolable;area very bright red at site and around circumference of thigh; no T; apap given;ice packs & dph applied;no more pertussis for pt;
Information has been received from a nurse regarding a patient of unknown age and gender. On 01-JUL-2014, the patient received expired M-M-R II (lot # H012572, expiration date 29-JUN-2014, route was not provided). The nurse reported that M-M-R II had no prior temperature excursions. No adverse symptoms reported. Additional information has been requested.
This case was reported by a other health professional via call center representative and described the occurrence of erythema in a adult patient who received FLUARIX QUADRIVALENT (batch number 5C2L4, expiry date 18th June 2016). This case was associated with a product complaint. In September 2015, the patient received FLUARIX QUADRIVALENT (intramuscular) .5 ml. On an unknown date, less than a week after receiving FLUARIX QUADRIVALENT, the patient experienced erythema and pharmaceutical product complaint. On an unknown date, the outcome of the erythema and pharmaceutical product complaint were unknown. The reporter considered the erythema to be probably related to FLUARIX QUADRIVALENT. Additional details provided were as follows: This case was reported by a pharmacy buyer. On 15th September 2015 or after (exact date of administration unknown), the patient received FLUARIX QUADRIVALENT on an unknown arm. The patient experienced localized redness around injection site and on arm. This is one of the five cases reported by the same reporter (see cases US2015133738, US2015133740, US2015133760 and US2015133773). The reporter was questioning about a specific lot administered to patients therefore filed related quality product complaint. At the time of reporting, any further details were not known by the reporter.
3 days after the first shot, rashes would appear on random areas all over body and would disappear within 20-30 mins. These are giant red welts and hive like rashes. Diagnosed as dermatographia. Never had this condition prior to receiving the first dose and condition is still continuing almost a month after second dose.
Pt. reported that he had a horrible headache from his first shot in this series and he wanted to go to the ER before the headache became severe.  Pt. was given ketorolac in the ER.
rash that develops on his chest, sides, and arms; rash itches once in a while; red spots; rash turns white; This case was reported by a consumer via call center representative and described the occurrence of rash in a 71-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose intramuscularly in unspecified arm at same pharmacy in November 2021). Additional patient notes included Never had an allergic reaction to anything during his lifetime.   In February 2022, the patient received the 2nd dose of Shingrix (intramuscular). On an unknown date, less than a week after receiving Shingrix, the patient experienced rash, itchy rash, red spotty rash and skin discoloration. On an unknown date, the outcome of the rash, itchy rash, red spotty rash and skin discoloration were not recovered/not resolved.   The reporter considered the rash to be related to Shingrix. It was unknown if the reporter considered the itchy rash, red spotty rash and skin discoloration to be related to Shingrix.     Additional Information: GSK Receipt Date: 29-Jul-2022 Reporter's Comments: The patient self-reported this case. The patient received his second shot of Shingrix on an unknown arm at the end of February 2022, he did not have the exact date (or lot number of the Shingrix administered) but did provide his pharmacy's contact information since they should have that information on file. Since receiving the second shot, the patient had a rash that developed on his chest, sides and arms. The patient had not seen a doctor about this including his primary care doctor; he had an appointment to see a dermatologist on Monday (01st August 2022). The patient had been self-treating with an unspecified generic inexpensive cream, which had Vaseline in it. He said the rash itched once in a while but did not hurt; and it hadn't gotten any worse. The patient stated that he had to put the cream on his arms when he went out in public because the cream leaved red spots, but one could barely see them, otherwise the rash turned white. Patient was unsure if his rash would be considered hives. The reporter consented to follow up.
PRESENTING PROBLEM:  Hypoxia [R09.02] COVID-19 virus infection [U07.1] Pneumonia due to COVID-19 virus [U07.1, J12.82]   HOSPITAL COURSE: 58-year-old lady with medical history of bipolar disorder, chronic obstructive pulmonary disease, cervical cancer, cognitive impairment presenting with dyspnea, fever, dry cough, headaches and chills for 1 day.  In ER patient was found to be COVID positive.  Upon ambulation she had hypoxia to 87%.  Patient's rest of the labs unremarkable.  Chest x-ray without any infiltrates.  No concerns for superimposed bacterial infection.  She was started on 6 mg dexamethasone and kept overnight for observation.  In the morning patient was able to walk without getting short of breath or hypoxic.  Patient had no complaints including no dyspnea are chest pain or cough or nausea or vomiting.  Patient was advised to take dexamethasone for total of 10 days.  She was also advised to be compliant with her home inhalers (which she has not been using lately).  Patient was discharged in stable condition to home with family.  ER return precautions also given.
Headache ,fever, body aches,chills , muscle cramps ,nausea  36 hours
no adverse effect; first dose on 11/8/18, her second dose was on 2/7/2019 and her third dose was on 11/13/2019; This spontaneous report was received from a female patient of unknown age reporting on herself. No information regarding the patient's medical history, concurrent conditions or concomitant medications was provided.  On 08-NOV-2018, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (route of administration, anatomical location, lot# and expiry date were not reported) for prophylaxis. On 07-FEB-2019, she received the second dose of  hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (route of administration, anatomical location, lot# and expiry date were not reported) for prophylaxis, and on 13-NOV-2019, the third dose of  hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (route of administration, anatomical location, lot# and expiry date were not reported) for prophylaxis was administered (inappropriate schedule of product administration). No adverse effects were reported.
I had a cough and chest pain.  I did not get a fever.  I was very tired.  I did have rebound COVID-19 as well.
Outbreak of shingles (herpes zoster), red painful itchy rash initially, resolved to recognizable blister appearance within 3-4 days
can not get erection; constantly itching on the sides of the face and other areas of body; cannot focus; get confused about stuff; feel weak; urinate about 20 to 30 times a day; urinate about 20 to 30 times a day and it smells horrible; This spontaneous case was reported by a consumer and describes the occurrence of ERECTILE DYSFUNCTION (can not get erection) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ERECTILE DYSFUNCTION (can not get erection) (seriousness criterion medically significant), PRURITUS (constantly itching on the sides of the face and other areas of body), DISTURBANCE IN ATTENTION (cannot focus), CONFUSIONAL STATE (get confused about stuff), ASTHENIA (feel weak), POLLAKIURIA (urinate about 20 to 30 times a day) and URINE ODOUR ABNORMAL (urinate about 20 to 30 times a day and it smells horrible). At the time of the report, ERECTILE DYSFUNCTION (can not get erection), PRURITUS (constantly itching on the sides of the face and other areas of body), DISTURBANCE IN ATTENTION (cannot focus), CONFUSIONAL STATE (get confused about stuff), ASTHENIA (feel weak), POLLAKIURIA (urinate about 20 to 30 times a day) and URINE ODOUR ABNORMAL (urinate about 20 to 30 times a day and it smells horrible) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was provided. No treatment information was provided.  It was reported that the patient had some medical side effects due to Moderna vaccine. The patient had none of these problems prior to taking vaccine.  Company comment: This case concerns a patient of unknown age and gender with no reported medical history, who experienced the unexpected serious event of Erectile dysfunction unspecified days after receiving unspecified dose of mRNA-1273 Vaccine. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This case concerns a patient of unknown age and gender with no reported medical history, who experienced the unexpected serious event of Erectile dysfunction unspecified days after receiving unspecified dose of mRNA-1273 Vaccine. The benefit-risk relationship of mRNA-1273 is not affected by this report.
pt received vaccine at 1550.  As she walked through the clinic on the way to exit, she felt dizzy.  Staff brought chair and recorded vital signs.  Pt was given water and VS repeated five mins later.  Pt stated she felt better so staff assisted pt to sit in waiting area.  Pt began to shake and stated she was dizzy again.  Vitals recorded,  Pt alerted staff that she consumed an energy drink before coming for vaccine.  RN monitored pt and pt status did not improve, so RN brought pt to ED in wheelchair accompanied by pt's family.  RN handed pt off to ED staff and gave brief report at 1630.
Polymyalgia Rheumatica - Pt had swelling of joints and muscles.  Very difficult to move to the point of not being able to get out of bed.  Treated with a month of Prednisone 20mg daily and has been on Prenisone 10mg daily since.
Fever, fatigue, body aches/chills,-headache  lasting 48 hours. Extreme dizziness, nausea, headache, fatigue, vertigo symptoms, (pain in right ear), loss of balance- lasting 10 days and continuing
Raised, erythematous, warm papule approximately 9 by 6 cm; agitated, angry behavior; difficulty catching breath.
This spontaneous report as received from a nurse refers to unspecified number of patients of unknown age and gender. The patient's current conditions and medical history were not reported. On an unknown date, the patients were vaccinated with unspecified doses of improperly stored (Oka/Merck) VARIVAX injection (unknown strength and route) (incorrect product storage). No adverse effect was reported. The outcome of the events was unknown. There was no product quality complaint involved. Additional information has been requested.
local redness & swelling 20x60mm;rt leg swollen noticed this AM;urticaria & edema;dx local rxn to DTAP;
Patient given HPV, Hep A, ADACEL and MENACTRA. Within 1-2 min after vaccine given patient fainted only out less than 1 minute. Then acting fine.
Moderna COVID-19 Vaccine EUA Pain in arm 12 hours after injection. Light headedness, headache, tiredness 19 hours after injection Mild fever (99.7) 20 hours after injection
I have been diagnosed with unexplained infertility after one year of trying and I have a previous child.
pt received booster dose only 3 months after 2nd dose Moderna. Received booster inadvertently 3 months earlier than 6 month recommended time frame
COVID patients after weeks of none; COVID patients after weeks of none; This is a spontaneous report from a non-contactable physician. A 58-year-old female patient received second dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number and Expiry date not reported), via an unspecified route of administration on an unknown date in Jan2021 (age at vaccination: 58-years-old) as dose 2, single for covid-19 immunisation. Medical history included rheumatoid arthritis from an unknown date and unknown if ongoing she was also on a biological for rheumatoid arthritis. The patient concomitant medications were not reported. Previously, patient received first dose of BNT162B2 (Lot number not reported) on an unknown date in Jan 2021 for covid-19 immunization. The patient underwent lab tests and procedures which included sars-cov-2 test: positive an unknown date. The patient was fully vaccinated in Jan 2021 and presented with a cough and severe headache. The patient had covid-19. The physician had seen covid patient after weeks of none. Her case makes more sense because she was also on a biological for rheumatoid arthritis and her presentation was more classic. The physician reported that they had stopped covid testing on fully vaccinated asymptomatic people a couple of weeks ago, so should they go back doing that. And response was provided to developing a testing approach that not only looks at vaccination status, but also takes into consideration your community prevalence (either test positivity or of new cases/100K, for example) and host factors (immunocompromised patients, those that live in congregate settings, persons with known close contact/household exposure, etc. The outcome of events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Temp went up to 101; hardly slept; she was unable to work; Whole body aches; Small blister on lower lip; lip soreness; coughing; wheezing; having difficulty breathing; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 62-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 2 intramuscular on 28Apr2021 09:00 (at the age of 62-Years-old) (Batch/Lot Number: EL3247) as DOSE 2, SINGLE for covid-19 immunisation. Medical history included Epicondylitis of arms and knees. Concomitant medication included losartan taken for unspecified indication and folic acid taken for an unspecified indication and Oxtrexup within 2 weeks of vaccination. The patient received first dose of BNT162B2 PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 1, intramuscular administered in left arm on 07Apr2021 09:00 (at the age of 62-Years-old) (Batch/Lot Number: EL3247) as DOSE 1, SINGLE for covid-19 immunisation. On 29Apr2021, the patient temperature went up to 101, temperature went up to 101 around 3am this morning, down to 100 at 7:46am, for 2 days and body aches, hardly slept and low-grade fever from 99-100 for 5 days. Small blister on lower lip appeared on 2d day after vaccine, coughing and wheezing started on 2nd day after vaccine and still as of today have needed to use nebulizer every day as patient had difficulty breathing. She used Neosporin on lips for blisters on lower lip - not visible now but can still feel lip soreness. As of today, Thursday, May 6, Still coughing and having difficulty breathing and needing to nebulize. Patient took Tylenol and drank fluids, etc. The patient underwent lab tests and procedures which included body temperature and showed 101 Fahrenheit on Mar2021, sars-cov-2 test was negative on Mar2021. Patient did not receive any other vaccines within 4 weeks prior to the COVID. Patient was diagnosed with COVID-19 Prior to vaccination. Patient was not tested for COVID-19, since the vaccination. Therapeutic measures were taken as a result of events. At the time of this report, the outcome of event was not recovered.  No follow-up attempts are needed. No further information is expected.
sore arm; he noticed a big red circle around the injection site, which is white in the middle; he noticed a big red circle around the injection site, which is white in the middle and warm as well; he noticed a big red circle around the injection site; injection site started itching badly; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm), VACCINATION SITE DISCOLOURATION (he noticed a big red circle around the injection site, which is white in the middle), VACCINATION SITE WARMTH (he noticed a big red circle around the injection site, which is white in the middle and warm as well), VACCINATION SITE ERYTHEMA (he noticed a big red circle around the injection site) and VACCINATION SITE PRURITUS (injection site started itching badly) in a 25-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 059E21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Aug-2021, the patient experienced VACCINATION SITE PRURITUS (injection site started itching badly). On 04-Aug-2021, the patient experienced VACCINATION SITE DISCOLOURATION (he noticed a big red circle around the injection site, which is white in the middle), VACCINATION SITE WARMTH (he noticed a big red circle around the injection site, which is white in the middle and warm as well) and VACCINATION SITE ERYTHEMA (he noticed a big red circle around the injection site). On an unknown date, the patient experienced PAIN IN EXTREMITY (sore arm). At the time of the report, PAIN IN EXTREMITY (sore arm) had resolved and VACCINATION SITE DISCOLOURATION (he noticed a big red circle around the injection site, which is white in the middle), VACCINATION SITE WARMTH (he noticed a big red circle around the injection site, which is white in the middle and warm as well), VACCINATION SITE ERYTHEMA (he noticed a big red circle around the injection site) and VACCINATION SITE PRURITUS (injection site started itching badly) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications included vitamins and topical medications for acne was reported. Patient advised did not take anything to treat the symptoms.
Janssen COVID-19 Vaccine EUA At post injection time 6 hours, I began feeling ill with chills, but no fever.   Then at 9 hours after injection, I began being nauseated and began vomiting.  The vomiting continued about every hour for the next 11 hours, feeling very ill between, and unable to keep down even sips of water.  Also had a mild headache, but still no fever.  Just very extreme nausea.  After 11 hours, the vomiting stopped.  I felt tired and nauseated for about 2 more days, then improved.
swelling throat/ear canal on right side; swelling throat/ear canal on right side; right face numbness/spread to my lips and up into my eye and ultimately radiating throughout my head; right face numbness/spread to my lips and up into my eye and ultimately radiating throughout my head; right face numbness/spread to my lips and up into my eye and ultimately radiating throughout my head; This is a spontaneous report from contactable consumers (one was patient). A 56-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EL9265, expiry date not reported), via an unspecified route of administration at the right arm on 30Jan2021 10:30 at single dose for COVID-19 immunization. Medical history included food allergy (reported as allergy to walnuts). The patient was not pregnant at the time of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was vaccinated at a workplace clinic. The patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient has not been tested for COVID-19. Concomitant medications were not reported. On 30Jan2021 10:45, both times the patient had right face numbness (felt like Novocaine) that started in her right cheek and spread to her lips and up into her eye and ultimately radiating throughout her head, and also swelling throat/ear canal on right side. It was unknown if treatment was received for the events. Clinical outcome of the events was not recovered.